United States· US:50419-253_4919c19b-7cbb-4724-a711-7f908b7d18e7
Adempas
A riociguat product containing riociguat, registered in United States by Bayer HealthCare Pharmaceuticals Inc.. The same ATC class is registered in 17 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Riociguat is registered in 17 of 19 countries.
Countries holding a registration under ATC C02KX05 (riociguat), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Riociguat · ATC C02KX05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of riociguat costs, country by country.
Normalised to the WHO defined daily dose (4.5 mg), the median price runs from $0.056 in France to $219.06 in Switzerland — a ×3926 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Riociguat · price per daily dose (4.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$219.06
- IT Italy$147.94
- FR France$0.056
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RIOCIGUAT
- Manufacturer
- Bayer HealthCare Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- C02KX05
- ATC class
- Riociguat
- Defined daily dose
- 4.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 16, 2026
Packs & prices · 6
- ndc11504192530190 TABLET, FILM COATED in 1 BOTTLE (50419-253-01)
- ndc1150419253032 BLISTER PACK in 1 PACKAGE (50419-253-03) / 21 TABLET, FILM COATED in 1 BLISTER PACK
- ndc1150419253919 TABLET, FILM COATED in 1 BOTTLE (50419-253-91)
- ndc1150419-253-01
- ndc1150419-253-03
- ndc1150419-253-91
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
140 interactions on record for riociguat.
Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Riociguat · interactions on record
140 records
- 10 severe
- 103 moderate
Most severe, free to view
- DipyridamoleB01AC07severe
- DipyridamolC01DX29severe
- TheophyllinC01EB28severe
- KetoconazoleH02CA03severe
27 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Riociguat in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAdempasOrifarm Oy
- SwedenAdempas 2 mg Filmdragerad tablettBayer AG
- CzechiaADEMPASBayer AG, Leverkusen
- NorwayAdempasBayer AG
- NetherlandsAdempas 2 mg, filmomhulde tablettenBayer AG
- SpainADEMPAS 2 mg comprimidos recubiertos con peliculaBayer Ag
- SwitzerlandAdempas
- IcelandAdempasBayer AG*
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Austria · Pahrilan
- Cyprus · Ridecia
- Finland · Midive, Riociguat
- Greece · Ridecia, Riociguat Win Medica
- Iceland · Adempas
- Liechtenstein · Adempas
- Malta · Midive, Riociguat
- Netherlands · Pahrilan
- Norway · Adempas
- Sweden · Pahrilan, Ridecia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9ee983c0-e79b-4cc4-b0ee-90e5afcf7c06 GET /v1/drugs/9ee983c0-e79b-4cc4-b0ee-90e5afcf7c06?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "2",
"substance": "RIOCIGUAT",
"productndc": "50419-253",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA204819",
"marketing_category": "NDA"
}See everything about riociguat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.